Germany’s Merck KGaA lifted its earnings forecast range for 2026 on Thursday and posted better-than-expected quarterly results on further gains in demand for its drug manufacturing supplies and semiconductor materials.
Financial Outlook
The diversified family-controlled group said earnings before interest, taxes, depreciation and amortisation (EBITDA), adjusted for special items, would likely rise to between €5.9 billion and €6.3 billion ($6.8-7.3 billion). Previously, it expected EBITDA in the €5.7 billion to €6.1 billion range. Last year, the company reported €6.1 billion.
In June, Merck boosted its Life Science unit, which makes drug research and manufacturing tools, by striking an $11.3 billion deal to buy Bio-Techne, its biggest transaction in more than a decade.
Original reporting: Appleton, WI News Feed (HLL/CB) — read the source article.
